While BRCA1 and BRCA2 mutations are well-established indicators of homologous recombination deficiency (HRD), not all patients with HRD respond equally to PARP inhibition. This evidence concerns the gene BRCA1 and hypoparathyroidism-retardation-dysmorphism syndrome.